• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Lucid Diagnostics Inc.

    2/13/25 1:38:10 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care
    Get the next $LUCD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    LUCID DIAGNOSTICS INC.

    (Name of Issuer)


    Common Stock, $0.001 par value

    (Title of Class of Securities)


    54948X109

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    54948X109


    1Names of Reporting Persons

    Ayrton Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,200,485.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,200,485.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,200,485.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    54948X109


    1Names of Reporting Persons

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,200,485.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,200,485.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,200,485.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    54948X109


    1Names of Reporting Persons

    Waqas Khatri
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,200,485.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,200,485.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,200,485.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    LUCID DIAGNOSTICS INC.
    (b)Address of issuer's principal executive offices:

    360 Madison Avenue, 25th Floor New York NY 10017
    Item 2. 
    (a)Name of person filing:

    (i) Ayrton Capital LLC; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B; (iii) Waqas Khatri
    (b)Address or principal business office or, if none, residence:

    (i) Ayrton Capital LLC, 55 Post Rd West, 2nd Floor Westport, CT 06880; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Suite #7 Grand Pavilion Commercial Centre, 802 West Bay Road, Grand Cayman, P.O. Box 10250, Cayman Islands; and (iii) Waqas Khatri 55 Post Rd West, 2nd Floor Westport, CT 06880
    (c)Citizenship:

    (i) Ayrton Capital LLC: United States; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: Cayman Islands; and (iii) Waqas Khatri: United States
    (d)Title of class of securities:

    Common Stock, $0.001 par value
    (e)CUSIP No.:

    54948X109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Ayrton Capital LLC: 1,200,485; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 1,200,485; and (iii) Waqas Khatri: 1,200,485. Represents 1,200,485 shares of Common Stock held by the Reporting Persons. The Shares reported herein represent Common Stock of Lucid Diagnostics Inc. (the "Issuer") held by Alto Opportunity Master Fund, SPC- Segregated Master Portfolio B, a Cayman Islands exempted company (the "Fund"). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the "Investment Manager"), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the "Reporting Persons").
    (b)Percent of class:

    The percentage below are based on 59,342,479 shares of Common Stock of the Issuer that were outstanding as of November 8, 2024. The amount of shares outstanding was based upon a statement in the Issuer's Form 10-Q, filed on November 12, 2024. For the sake of clarity, the holdings of the Reporting Persons reported herein are as of December 31, 2024. (i) Ayrton Capital LLC: 2.0%; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 2.0%; and (iii) Waqas Khatri: 2.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 1,200,485; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 1,200,485; and (iii) Waqas Khatri: 1,200,485

     (ii) Shared power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; and (iii) Waqas Khatri: 0

     (iii) Sole power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 1,200,485; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 1,200,485; and (iii) Waqas Khatri: 1,200,485

     (iv) Shared power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; and (iii) Waqas Khatri: 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ayrton Capital LLC
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Managing Member
    Date:02/13/2025
     
    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Director
    Date:02/13/2025
     
    Waqas Khatri
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri
    Date:02/13/2025
    Get the next $LUCD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LUCD

    DatePrice TargetRatingAnalyst
    12/27/2021$16.00Buy
    Ascendiant Capital
    12/15/2021$17.00 → $13.00Buy
    Needham
    11/8/2021$18.00Buy
    Canaccord Genuity
    11/8/2021$14.00Buy
    BTIG Research
    11/8/2021$21.00Overweight
    Cantor Fitzgerald
    11/8/2021$17.00Buy
    Needham
    More analyst ratings

    $LUCD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

    Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's

    2/4/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

    NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test, expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually. The contract is issued under the VA Federal Supply Schedu

    1/21/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Announces Reverse Stock Split

    NEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it will conduct a 1-for-30 reverse stock split of its common stock (the "Common Stock"). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "PAVM" and will begin trading on a split-adjusted basis at the opening of the market on January 2, 2026. The reverse stock split is intended to bring the Company into

    12/30/25 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

    5/27/25 7:31:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Lucid Diagnostics Inc.

    SCHEDULE 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    2/9/26 6:41:17 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Lucid Diagnostics Inc.

    S-3 - Lucid Diagnostics Inc. (0001799011) (Filer)

    12/5/25 5:01:46 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Lucid Diagnostics Inc. (0001799011) (Filer)

    11/12/25 8:15:37 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital initiated coverage on Lucid Diagnostics with a new price target

    Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00

    12/27/21 6:21:16 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on Lucid Diagnostics with a new price target

    Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously

    12/15/21 6:36:10 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Lucid Diagnostics with a new price target

    Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00

    11/8/21 10:16:23 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Palumbo John R

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    10/7/25 4:46:05 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    New insider Palumbo John R claimed ownership of 47,857 shares (SEC Form 3)

    3 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    10/7/25 4:45:33 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Director Matheis Dennis bought $101,840 worth of shares (100,000 units at $1.02), increasing direct ownership by 18% to 665,443 units (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    8/22/25 5:17:58 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matheis Dennis bought $101,840 worth of shares (100,000 units at $1.02), increasing direct ownership by 18% to 665,443 units (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    8/22/25 5:17:58 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

    4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)

    5/23/25 4:14:42 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31) (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    5/22/25 4:45:49 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

    SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    12/12/24 4:30:32 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lucid Diagnostics Inc.

    SC 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    7/8/24 3:49:29 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Lucid Diagnostics Inc. (Amendment)

    SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    2/20/24 4:45:37 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    Financials

    Live finance-specific insights

    View All

    PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's thi

    10/30/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2025 f

    10/29/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

    Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molec

    9/5/25 9:16:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care